E-resources
-
Fukuhara, Tatsuro; Saito, Haruhiro; Furuya, Naoki; Watanabe, Kana; Sugawara, Shunichi; Iwasawa, Shunichiro; Tsunezuka, Yoshio; Yamaguchi, Ou; Okada, Prof Morihito; Yoshimori, Kozo; Nakachi, Ichiro; Gemma, Prof Akihiko; Azuma, Koichi; Kurimoto, Futoshi; Tsubata, Yukari; Fujita, Yuka; Nagashima, Hiromi; Asai, Gyo; Watanabe, Satoshi; Miyazaki, Masaki; Hagiwara, Prof Koichi; Nukiwa, Prof Toshihiro; Morita, Prof Satoshi; Kobayashi, Prof Kunihiko; Maemondo, Prof Makoto
EBioMedicine, 07/2020, Volume: 57Journal Article
The NEJ026 Phase 3 study demonstrated that erlotinib and bevacizumab (BE)-treated NSCLC patients with EGFR mutations had significantly better progression-free survival (PFS) than those treated with erlotinib alone (E). This study included a prospective analysis of the relationship between the mutational status of EGFR in plasma circulating tumor DNA (ctDNA) and the efficacy of TKI monotherapy or combination therapy. We describe these results herein. Plasma samples were collected from patients enrolled in NEJ026 at the start of treatment (P0), 6 weeks after the start of treatment (P1), and upon confirmation of progressive disease (P2). Plasma ctDNA was analyzed using a modified PNA-LNA PCR clamp method. PFS and OS according to EGFR status at the time of plasma collection were evaluated. Plasma activating EGFR mutation (aEGFR) at P0 was detected in 68% of cases; patients without plasma aEGFR had longer PFS. The frequency of T790M mutation at P2 was similar in both arms: 8 (19.0%) in BE and 11 (20.8%) in E. Based on the aEGFR profiles, PFS was evaluated among three groups: type A P0(-), P1(-), type B P0(+), P1(-), and type C P0(+), P1(+). This revealed that BE was more efficacious than E, and that BE was associated with improved PFS in all types. Pre-treatment plasma aEGFR status have a potential of early predictor of response of TKI efficacy. Monitoring plasma aEGFR mutation will contribute to selection and continuation of treatment with BE or E. Chugai Pharmaceutical.
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.